These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20411161)

  • 1. The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves' disease.
    van Isselt JW; Broekhuizen-de Gast HS
    Hell J Nucl Med; 2010; 13(1):2-5. PubMed ID: 20411161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of the possibility of curing Graves' disease based on the desired reduction of thyroid mass (volume) as a consequence of 131I therapy: a speculative paper.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Nucl Med Commun; 2006 May; 27(5):439-46. PubMed ID: 16609355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [F-qi-FDG PET of the thyroid gland in Graves' disease].
    Börner AR; Voth E; Wienhard K; Wagner R; Schicha H
    Nuklearmedizin; 1998; 37(7):227-33. PubMed ID: 9830612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves' disease.
    Dunkelmann S; Kuenstner H; Nabavi E; Rohde B; Groth P; Schuemichen C
    Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):228-36. PubMed ID: 17021811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calculation of therapeutic activity of radioiodine in Graves' disease by means of Marinelli's formula, using technetium (
    Szumowski P; Mojsak M; Abdelrazek S; Sykała M; Amelian-Fiłonowicz A; Jurgilewicz D; Myśliwiec J
    Endocrine; 2016 Dec; 54(3):751-756. PubMed ID: 27553050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dosimetric approach to patient-specific radioiodine treatment of Graves' disease with incorporation of treatment-induced changes in thyroid mass.
    Traino AC; Di Martino F; Lazzeri M
    Med Phys; 2004 Jul; 31(7):2121-7. PubMed ID: 15305466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose metabolism of the thyroid in Graves' disease measured by F-18-fluoro-deoxyglucose positron emission tomography.
    Boerner AR; Voth E; Theissen P; Wienhard K; Wagner R; Schicha H
    Thyroid; 1998 Sep; 8(9):765-72. PubMed ID: 9777746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients.
    Canzi C; Zito F; Voltini F; Reschini E; Gerundini P
    Med Phys; 2006 Aug; 33(8):2860-7. PubMed ID: 16964862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.
    Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimized radioiodine therapy for Graves' disease: two MIRD-based models for the computation of patient-specific therapeutic 131I activity.
    Carlier T; Salaun PY; Cavarec MB; Valette F; Turzo A; Bardiès M; Bizais Y; Couturier O
    Nucl Med Commun; 2006 Jul; 27(7):559-66. PubMed ID: 16794516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The outcome of treatment with adjusted dose of 131I to thyroid weight for Graves' disease by estimation of effective half life using a single radioiodine uptake measurement].
    Gomi Y; Watanabe M; Yoshimura H; Ishikawa N; Momotani N; Ito K; Inoue T; Ito K; Suzuki S
    Kaku Igaku; 2000 Mar; 37(2):109-14. PubMed ID: 10783569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
    Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H
    Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Does an individual estimation of halflife improve the results of radioiodine therapy of Graves' disease?].
    Walter MA; Müller B; Müller-Brand J
    Nuklearmedizin; 2003 Jun; 42(3):N29; author reply N29. PubMed ID: 12848158
    [No Abstract]   [Full Text] [Related]  

  • 15. Investigation of biokinetics of radioiodine with a population kinetics approach.
    Janzen T; Giussani A; Canzi C; Gerundini P; Oeh U; Hoeschen C
    Radiat Prot Dosimetry; 2010; 139(1-3):232-5. PubMed ID: 20172932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Estimation of effective half life of 131I in radioiodine therapy for Graves' disease using a single radioiodine uptake measurement].
    Watanabe M; Ito K; Mimura T; Ishikawa N; Ino E; Saitoh T; Tsuji H; Tsuchiya T
    Kaku Igaku; 1993 Sep; 30(9):1055-62. PubMed ID: 8230826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine therapy in Graves' disease: is it possible to predict outcome before therapy?
    Isgoren S; Daglioz Gorur G; Demir H; Berk F
    Nucl Med Commun; 2012 Aug; 33(8):859-63. PubMed ID: 22669051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
    Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
    Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining thyroid (131)I effective half-life for the treatment planning of Graves' disease.
    Willegaignon J; Sapienza MT; Coura Filho GB; Traino AC; Buchpiguel CA
    Med Phys; 2013 Feb; 40(2):022502. PubMed ID: 23387769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE; Michanek AM; Holmberg EC; Fink M
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.